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Abstract
Background: Genetic factors are important in determining breast density, and heritable factors account for 60% of the
variation. Certain single nucleotide polymorphisms (SNPs) are associated with density and risk of breast cancer but the
association with prognosis is not clear.
Purpose: To investigate associations between selected SNPs and breast cancer survival in the Malm€o Diet and Cancer
Study (MDCS).
Material and Methods: A total of 724 unrelated women with breast cancer and registered radiological and patho-
logical data were identified in MDCS 1991–2007, with genotyping available for 672 women. Associations among
15 SNPs, density, and breast cancer-specific survival were analyzed using logistic/Cox regression, adjusted for factors
affecting density and survival. Variants significantly associated with either density or survival were validated in a large
independent breast cancer cohort (LIBRO-1).
Results: Minor homozygotes of SNPs rs9383589, CCDC170 and rs6557161, ESR1 were associated with high breast
density (adjusted odds ratio [AOR] 8.97, 95% confidence interval [CI] 1.35–59.57; AOR 2.08, 95% CI 1.19–3.65,
respectively) and poorer breast cancer survival (adjusted hazard ratio [HRadj] 6.46, 95% CI 1.95–21.39; HRadj 2.30,
95% CI 1.33–3.96, respectively) compared to major homozygotes. For SNP rs3757318, ESR1, minor homozygotes
(HRadj 7.46, 95% CI 2.28–24.45) were associated with poorer survival. We confirmed that rs6557161, ESR1 was
significantly associated with both density and survival in the LIBRO-1 study.
Conclusion: These findings support a shared genetic basis for density and breast cancer survival. The SNP significantly
associated with both density and survival in both cohorts may be of interest in future research investigating polygenic
risk scores for breast cancer risk and screening stratification purposes.
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Introduction
Breast cancer prognosis has improved over the years
due to advances in diagnostics and treatments. Still,
522,000 women die of breast cancer each year,
making breast cancer the fifth most common cause of
death among women worldwide (1). Understanding
factors related to breast cancer survival is paramount
in order to identify women at risk for fatal breast
cancer at earlier stages of the disease.
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Breast imaging is a central priority for prevention
and treatment (2). Breast density is a readily available
mammographic biomarker and high density has proven
to be associated with increased risk of breast cancer (3).
Previous studies on density and survival are inconclu-
sive with some publications not showing an association
(4,5), but some, including a study on the cohort
described in the present study (6), report an impaired
survival with higher density (6,7). Further speaking for
a role of density in survival is the notion that women
responding with decreased density during tamoxifen
treatment have a better prognosis (8). The biological
links between density, risk of breast cancer, and surviv-
al are complex and not yet fully understood. However,
a recent review suggested a possible biological
mechanism involving stroma cells and proteins (e.g.
fibroblasts, immune cells, and collagen), which may
contribute to or facilitate breast cancer development
and progression (9).
In addition to the well-known, high-penetrance
genes that increase the risk of breast cancer, the aggre-
gate polygenetic effect of low-penetrant variants (i.e.
single nucleotide polymorphisms [SNPs]) may contrib-
ute at least 14% to the heritability of breast cancer (2).
Several SNPs are associated with breast density param-
eters and risk of breast cancer (10,11). Further, there
may be genetic components common to risk of breast
cancer and prognosis (12–14). Speaking against, how-
ever, a previous large study including several SNPs
showed that there was no evidence that any of the
SNPs associated with breast cancer susceptibility
were associated with breast cancer survival (15).
Importantly, none of the previously mentioned studies
on risk of breast cancer and survival SNPs has consid-
ered density. This may be of importance since genetic
variants associated with breast density and breast
cancer survival may identify SNPs that could be used
to optimize present risk scores. Such improved risk
scores (based on image parameters, familial history,
and genetic factors) could be used to assess an individ-
ual’s breast cancer risk, as well as develop individual-
ized breast cancer screening programs (16,17).
The aim of this study was to examine the association
between breast density, breast cancer risk-associated
SNPs, and breast cancer-specific survival among
women participating in a large Swedish cohort study:
the Malm€o Diet and Cancer Study (MDCS) and with
replication in a second cohort.
Material and Methods
The Malm€o Diet and Cancer Study
The MDCS (LU 51-90) and the present study (Dnr
652/2005, Dnr 23/2007, and Dnr 2009/682) were
approved by the regional Ethical Committee in Lund,
Sweden. All women gave written informed consent.
The MDCS (18–20) was a population-based, pro-
spective cohort study, which included 17,035 women
(1991–1996). Cases of breast cancer were identified
prospectively, and the associated pathological and
radiological variables at breast cancer diagnosis (e.g.
categorical breast density, mammographic tumor
appearance, mode of detection) were collected and
added to the database, in addition to baseline variables.
The present study population (821 women) with exclu-
sions is shown in Fig. 1. Cause of death (breast cancer
as an underlying or subordinate cause of death) and
vital status (alive or dead from another cause than
breast cancer was classified as alive) was registered
with last follow-up on 31 December 2016.
The LIBRO-1 study
The LIBRO-1 study was approved by the Regional
Ethical Review Board (registration no. 2009/254-31).
LIBRO-1 is a breast cancer cohort of patients diag-
nosed between 2001 and 2008 in the Stockholm/
Gotland area who gave informed consent. The study
was approved by the local ethics review board at
Karolinska Institutet. Breast cancer risk factors, socio-
economic factors, and reproductive events were
assessed by questionnaire. In addition, tumor charac-
teristics were retrieved from the Swedish cancer registry
and survival after breast cancer was ascertained from
the Swedish causes of death registry, as described
before with virtually no missing data (21). We only
included patients with invasive breast cancer with
available genotype information (see below).
Genotyping
DNA was extracted from stored blood samples and
genotyping was successful for 780 women before
study population exclusions (Fig. 1). Genotyping was
performed using the HumanOmniExpressExome-
BeadChip (OEE) version 1.0 or 1.1 Ch37 and iScan
System (Illumina, San Diego, CA, USA) according to
the manufacturer’s recommended protocols. The OEE
chip included 244,194 primarily exon markers and
706,924 markers for coverage of common genome-
wide variation. Analyses were performed at MIT’s
Broad Institute and Harvard (USA), in addition to
the Clinical Research Center (CRC) in Malm€o,
Sweden. During quality control (QC) for SNPs,
169,775 SNPs were excluded due to a lack of variation
in European populations (monomorphic SNPs), a devi-
ation from Hardy–Weinberg equilibrium in controls
(P< 106) or a variant call rate of <95% in all samples.
This resulted in approximately 750,000 SNPs
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remaining after QC. All QC was performed by using
PLINK version 1.07 software. We only included indi-
viduals with a call rate >95% and inbreeding coeffi-
cients of 0.2 to 0.2 to control for excess of
heterozygosity. Using identity by descent, shared first-
and second-degree relatives were identified. One of the
relatives was omitted, excluding five women (Fig. 1).
Genotyping of the LIBRO-1 patients was done through
the Breast Cancer Association Consortium (BCAC) on
a custom Ilumina iSelect genotyping array as part of
the Collaborative Oncological Gene-environment
Study (iCOGS) (22). Imputation and quality control
of variants and patients was performed as previously
described (23). Patients without genotype data or
which failed quality control were excluded. In total,
4431 breast cancer patients with genotype information
were included in this study in order to replicate signif-
icant findings in an independent cohort.
SNP selection
We selected 15 SNPs that are associated with breast
density and breast cancer risk from two recent meta-
analyses based on Genome Wide Association Studies
(GWAS) (10,11). Eight SNPs were not included on the
OEE chip, and a web-based tool, SNAP Proxy (24),
was used to identify SNPs with a linkage disequilibrium
(LD) of r2> 0.8 to the missing SNP. The SNPs, proxy
SNPs and genes are listed in Supplemental Table S1.
All selected SNPs had a minor allele frequency
(MAF)> 5% except for rs7289126 (MAF¼ 0.03).
Genomic data for the 15 candidate SNPs were avail-
able for 672 women after QC (Fig. 1).
Breast density
Breast density was graded (fat involuted/moderately
dense/dense) in the original radiology report of the
breast cancer diagnostic mammogram and retrospec-
tively retrieved for research purposes (6,25–27). The
classification can be regarded as a modified Breast
Imaging Reporting and Data System (BI-RADS)
4th Ed density categorization. “Fat involuted” corre-
sponded to BI-RADS 1 (almost entirely fat),
“moderately dense” to BI-RADS 2 and 3 (scattered
fibroglandular densities and heterogeneously dense),
and “dense” to BIRADS 4 (extremely dense). The
breast density was estimated using both breasts, and
all views were assessed by one of five experienced
Fig. 1. Study population and exclusions.
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breast radiologists (with >10 years of experience in
breast radiology).
In LIBRO-1, the breast density of each patient was
determined by a machine-learning based algorithm
called STRATUS (28) and coded as dense (BI-RADS
4) and non-dense/mixed (BI-RADS 1-3), as based on
BI-RADS 4th Ed. Breast density was measured at
mammogram closest to breast cancer diagnosis.
Statistical analyses
Selected SNPs were analyzed as categorical variables
(major homozygote allele (reference)/heterozygote/
minor homozygote allele). Logistic regression was
used to analyze SNPs in relation to dichotomized
breast density (fatty/mixed density versus dense),
which yielded odds ratios (OR) and 95% confidence
intervals (CI); adjustments were made for age at diag-
nosis (continuous), hormone replacement therapy
(HRT) at baseline (binary), and body mass index
(BMI) at baseline (continuous). Associations between
selected SNPs and breast cancer survival were analyzed
using Cox’s proportional hazards analysis, yielding an
HR with a 95% CI; adjustments were made for age at
diagnosis, tumor size (linear), axillary lymph node
involvement (ALNI) (binary), histological grade (cate-
gorical on three levels), and estrogen receptor (ER 10%
cut-off). In a second step, the survival analysis was
adjusted for HRT at baseline and BMI at baseline
(known determinants of breast density) in order to
study the independent effect of the SNP. No correction
for multiple testing was used, to avoid false negatives.
The proportional hazards assumption was confirmed
using a log-minus-log plot. Three women with unknown
vital status at emigration were categorized as alive and
included in analyses. For replication, we studied the
effect of significant SNPs on density and breast cancer
specific survival in 4431 patients with invasive breast
cancer from the LIBRO-1 study using corresponding
adjustment factors and statistical analyses. SPSS
Statistics for Windows was used for the statistical anal-
yses (v.25.0, IBM Corp., Armonk, NY, USA).
Results
Distributions of covariates in MDCS and LIBRO-1 are
summarized by frequencies and percentages by breast
cancer vital status (alive or dead from another cause vs.
breast cancer specific death) (Table 1). All analyzed
Table 1. Distributions of covariates by breast cancer vital status (alive/breast cancer death).
MDCS LIBRO-1
Alive Breast cancer death Alive Breast cancer death
Age at diagnosis (years) 63.8 (58.8–70.2) 64.5 (59.6–73.3) 59.0 (25.0–79.0) 59.5 (26.0–79.0)
Breast density
Fatty/mixed 342 (62.6) 62 (49.2) 2706 (64.8) 166 (65.9)
Dense 170 (31.1) 45 (35.7) 1098 (26.3) 48 (19.0)
Missing 34 (6.2) 19 (15.1) 375 (9.0) 38 (15.1)
BMI at baseline (kg/m2) 24.8 (22.7–27.8) 25.6 (23.4–28.5) 24.7 (16.0–50.4) 24.9 (16.7–44.6)
HRT at baseline
Yes 155 (28.4) 30 (24) 750 (17.9) 31 (12.3)
No 389 (71.2) 96 (76) 2785 (66.6) 183 (72.6)
Missing 2 (0.4) 0 644 (15.4) 38 (15.1)
Estrogen receptor
Positive 402 (73.6) 81 (64.3) 2930 (70.1) 162 (64.3)
Negative 53 (9.7) 23 (18.3) 480 (11.5) 40 (15.9)
Missing 91 (16.7) 22 (17.5) 769 (18.4) 50 (19.8)
Axillary lymph node involvement
Positive 124 (22.7) 77 (61.1) 1215 (29.1) 153 (60.7)
Negative 419 (76.7) 47 (37.3) 2707 (64.8) 76 (30.2)
Missing 3 (0.5) 2 (1.6) 257 (6.2) 23 (9.1)
Tumor size (mm) 14 (10–20) 22 (15–31) 15.0 (2.0–80.0) 22.0 (2.0–80.0)
Missing 6 (1.1) 9 (7.1) 112 (2.7) 15 (6.0)
Histological grade
I 159 (29.1) 12 (9.5) 542 (13.0) 4 (1.6)
II 255 (46.7) 47 (37.3) 1401 (33.5) 84 (33.3)
III 100 (18.3) 54 (42.9) 711 (17.0) 60 (23.8)
Missing 32 (5.9) 13 (10.3) 1525 (36.5) 104 (41.3)
Values are given as n (%) or median (range).
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SNPs in MDCS are described in Supplemental
Table S1.
SNPs and breast density
Significant associations among SNPs, breast density,
and breast cancer survival are shown in Table 2. For
rs9383589, CCDC170 (adjusted OR [AOR]¼ 8.97,
95% CI¼ 1.35–59.57) and rs6557161, ESR1 (AOR¼
2.08, 95% CI¼ 1.19–3.65), there was a significant asso-
ciation between minor homozygotes and high breast
density when compared to major homozygotes. In con-
trast, for rs7289126, TMEM184B, there was a signifi-
cant association between both heterozygotes
(AOR¼ 0.60, 95% CI¼ 0.40–0.90) and minor homo-
zygotes (AOR¼ 0.58, 95% CI¼ 0.35–0.97) with fatty/
mixed breast density when compared to major homo-
zygotes. For 12 of the selected SNPs, no significant
association with breast density was observed
(Supplemental Table S1).
SNPs and breast cancer survival
Minor homozygotes of SNP rs9383589, CCDC170
(adjusted hazard ratio [HRadj2]¼ 6.46, 95%
CI¼ 1.95–21.39) and rs6557161, ESR1 (HRadj2¼ 2.30,
95% CI¼ 1.33–3.96) were associated with impaired
breast cancer survival in both steps of adjustment
when compared to major homozygotes. For SNP
rs3757318, ESR1, minor homozygotes (HRadj2¼ 7.46,
95% CI¼ 2.28–24.45) were associated with impaired
breast cancer survival, but an association with density
was not established. For 12 of the selected SNPs, no
significant relationship to breast cancer survival was
shown.
Replication analysis
In the LIBRO-1 study, we were able to confirm a sig-
nificant association of rs6557161, ESR1 with breast
density (ORadj¼ 1.27, 95% CI¼ 1.08–1.50 and
ORadj¼ 1.35, 95% CI¼ 1.02–1.78 for heterozygotes
and homozygotes minor, respectively) (Table 3). For
the other SNPs, we did not find a significant associa-
tion with breast density, however, the effect sizes of
rs7289126 (heterozygotes and homozygote minors)
were in the same orientation as in the MDCS study,
although smaller. We found a significant effect of
rs6557151, ESR1 on breast cancer-specific survival
(HRcrude¼ 1.36, 95% CI¼ 1.04–1.77, heterozygotes)
and a borderline effect after first set of adjustment
(HRadj1¼ 1.67, 95% CI¼ 0.99–2.81, homozygote
minors). However, in the second set of adjustments
(adding BMI and HRT), no association was found.
For both, rs9383589, CCDC170 and rs3757318,
ESR1, no individuals with the homozygote minor
allele died due to breast cancer and, thus, we were
not able to compute meaningful HRs.
Discussion
This paper highlights SNPs known to be associated
with breast density and risk of breast cancer. This
research demonstrates their association with density
and impaired breast cancer survival in the MDCS
and confirm the association in the same orientation in
the LIBRO-1 study for the ESR1 SNP. To the best of
our knowledge, this is the first study to report these
associations. Our results support the hypothesis that
there might be a shared genetic basis for breast density
and breast cancer survival.
For rs6557161, ESR1 (proxy from rs2046210), there
was an association with high breast density and poorer
breast cancer survival in both MDCS and LIBRO-1.
However, after the second set of adjustment (BMI and
HRT) survival analyses (LIBRO-1), the association
could no longer be seen, but with effect sizes still in
the same direction as in MDCS. The potential reason
for this could be a sample size issue, since some cases
without data on BMI and HRT will be excluded from
analyses in the second set of adjustment. In addition,
previous studies on density and breast cancer-specific
survival differ on adjustment of BMI and HRT, which
questions their contribution in survival analyses (29).
The original SNP (rs2046210, ESR1) has previously
been associated with increased breast cancer risk and
prognosis (30,31), and the risk allele (A) has been asso-
ciated with higher breast density (11). The ESR1 gene
encodes the estrogen receptor, which regulates signal
transduction of estrogen and is central in breast carci-
nogenesis (32). In addition, the ESR1 gene has been
shown to be involved in bone mineral density, which
is also affected by estrogen (33).
The A allele of rs3757318, ESR1 has been shown to
correlate with increased risk of breast cancer and breast
density (11), and the A allele was associated with
poorer rates of breast cancer survival in the MDCS
in this study. However, its relationship with breast den-
sity could not be significantly established and a statis-
tically significant effect could not be replicated in the
LIBRO-1. Of course, the impact on breast cancer sur-
vival is complex and facilitated through several mech-
anisms in addition to breast density. Considering the
multifaceted roles of ESR1 discussed previously, this
could possibly involve estrogen-related mechanisms.
Homozygote minors of rs9383589, CCDC170
(proxy from rs12665607) were associated with high
breast density and poorer breast cancer survival in
the MDCS. About breast density, this finding is similar
to that of a previous study of the original SNP (10).
The CCDC170 gene is part of a breast cancer















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1332 Acta Radiologica 61(10)
susceptibility locus. Together with ESRI, it is involved
in breast cancer carcinogenesis and progression (31). In
addition, rs9383589, CCDC170 in normal tissues adja-
cent to a breast tumor is associated with lower BMIs
(31). This is interesting because BMI and breast density
are inversely correlated (9).
In a recent paper on breast cancer risk loci and sur-
vival, Barrdahl et al. (14) reported the influence of two
of 35 SNPs on overall survival in patients with breast
cancer. Specifically, they found that the C-allele of
rs3817198, LSP1 correlated with improved overall sur-
vival, and the T-allele of rs3803662, TNRC9 correlated
with poorer overall survival. These two SNPs and cor-
responding alleles were previously shown to be related
to increased breast density in another study (34).
Rs3817198, LSP1 was included in the present study,
but we could not recapitulate any association with den-
sity or survival.
There is an increasing interest in developing strati-
fied breast screening programs instead of the “one-size-
fits-all” approaches presently in use. Polygenic risk
scores (i.e. the combination of high-risk SNPs) in com-
bination with information on family history and breast
density could be used to achieve such a stratification
(16,17). However, it is not clear which factors to
include in such a score. If certain genetic factors (e.g.
certain SNPs) influence the association of density, risk
and survival, these SNPs would be of interest.
There was no formal assessment of inter-observer
variability for density grading in the MDCS.
However, same radiologists as in the present study
double-read 5928 mammograms with substantial den-
sity agreement (Œ¼ 0.77) (35). MDCS and LIBRO-1
used different density measurements, however, with
density categories carefully approximated to be compa-
rable. In the adjusted model in LIBRO-1, the effect
sizes for density were in the same orientation as in
MDCS, speaking in favor of the comparison. With 15
tested SNPs, one might suspect associations to be
chance findings as a type I error. However, the fact
that when associations were found, the associations
were in general not borderline significant (in terms of
CI) and the associations for two of the SNPs were pre-
sent for both density and survival analyses, this
strengthens our findings together with the replication
analysis.
Importantly, we were able to confirm our findings
on the ESR1 rs6557161 in a large collection of cases of
breast cancer from the LIBRO-1 study. Although only
rs6557161, ESR1 was statistically significantly associ-
ated with breast density and survival, one other SNP
(rs7289126) had effect sizes in the same orientation as
observed in the MDCS. Due to the smaller sample size
of the MDCS, the observed effect sizes might be more
subject to the winner’s curse effect and thus be
larger than the effect sizes observed in LIBRO-1.
Nevertheless, the results of this study strongly implicate
the role of known breast density variants in breast
cancer survival.
In conclusion, our findings support a shared genetic
basis for breast density and breast cancer survival, pre-
sumably representing shared etiologies. The SNP,
rs6557161, ESR1, significantly associated with both
breast density and survival in both cohorts may be of
interest in future research investigating polygenic risk
scores for risk of breast cancer and screening stratifica-
tion purposes.
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